Objectives To estimate the loss of quality of life and cost of treatment associated with genital
warts seen in sexual health clinics. Methods A cross-sectional questionnaire study and case …

Objectives To estimate for the first time the incidence and healthcare resource utilisation
associated with genital warts (GW) in Australia prior to the human papillomavirus …

Objectives To estimate the total number of cases of, and cost of care for, genital warts (GWs)
in England, to inform economic evaluations of human papillomavirus vaccination. Methods …

Background: Data on the burden of genital warts in terms of treatment costs and detriment to
quality of life (QoL) are required to assess cost-effectiveness of quadrivalent human …

OBJECTIVE: Worldwide, genital warts, caused by human papillomavirus (HPV) is a
common, sexually transmitted disease. The overall disease management strategy for genital …

Objective: This study examined the incidence of and healthcare costs attributable to genital
warts within a large US commercially insured, geographically dispersed population …

Background There has been a rapid decline in the number of young heterosexuals
diagnosed with genital warts at outpatient sexual health services since the national human …

Objectives To estimate the prevalence of, and describe risk factors for, genital warts (GWs) in
the British population, following the introduction of the bivalent (human papillomavirus (HPV) …

Objective The quadrivalent human papillomavirus (HPV) vaccine is effective against HPV
types responsible for 90% of anogenital warts. This study estimated the quality of life lost to …

Objectives: One of the two new human papillomavirus (HPV) vaccines protects against HPV
types 6 and 11, which cause over 95% of genital warts, in addition to protecting against HPV …